Published

Preclinical evaluation of psilocybin as an anti-inflammatory agent

No abstract is available for this record.

Open source BibTeX RIS

Bibliographic context

Journal: Neuroscience Applied
Date: 2025-12-31
Source: OpenAlex
DOI: 10.1016/j.nsa.2025.105853
PubMed: Unavailable

Authors

N. Martínez-Álvarez I. Erkizia-Santamaría A. Tomás-Alvarado A.M. Erdozain J.J. Meana J.E. Ortega

Watch author

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Preclinical evaluation of psilocybin as an anti-inflammatory agent2025-12-31

Related papers

Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: a case reportFrontiers in Neuroscience · 2026-05-27 Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic PotentialDigital Showcase Research, Scholarship, & Creative Works (University of Lynchburg) · 2026-05-21 Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in ratsCell Reports Medicine · 2026-05-31 Psilocybin-induced neurocardiogenic syncope: a case reportPsychopharmacology · 2026-05-27 Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim testJournal of Psychopharmacology · 2026-06-22 Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17 Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depressionPharmacological Research · 2026-06-10 Time to embrace the whole: considering the replacement of psilocybin with Psilocybe spp. in psychedelic research and therapyNatural Product Research · 2026-06-01